Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
|
|
ELI LILLY & Co (LLY)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 02/26/2021 |
GN
| U.S. Government to Purchase Minimum of 100,000 Doses of Etesevimab and Bamlanivimab Neutralizing Antibody Therapy |
| 02/10/2021 |
GN
| Etesevimab (JS016) Administered with Bamlanivimab Receives FDA Emergency Use Authorization for COVID-19 |
| 01/27/2021 |
GN
| Lilly, Vir Biotechnology and GSK Announce First Patient Dosed in Expanded BLAZE-4 Trial Evaluating Bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19 |
| 01/26/2021 |
GN
| New data show treatment with etesevimab (JS016) and bamlanivimab together reduced risk of COVID-19 hospitalizations and death by 70 percent |
| 12/16/2020 |
GN
| SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Prevail Therapeutics Inc. Buyout |
| 12/16/2020 |
GN
| PREVAIL THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of PRVL and Encourages Investors to Contact the Firm |
| 11/07/2020 |
GN
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Eli Lilly and Company - LLY |
| 10/26/2020 |
GN
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Eli Lilly and Company - LLY |
| 10/20/2020 |
GN
| ELI LILLY AND COMPANY ALERT: Bragar Eagel & Squire, P.C. is Investigating Eli Lilly and Company on Behalf of Eli Lilly Stockholders and Encourages Investors to Contact the Firm |
| 10/15/2020 |
GN
| ELI LILLY AND COMPANY ALERT: Bragar Eagel & Squire, P.C. is Investigating Eli Lilly and Company on Behalf of Eli Lilly Stockholders and Encourages Investors to Contact the Firm |
| 09/22/2020 |
GN
| Trulicity® (dulaglutide) is now indicated as an adjunct to diet, exercise, and standard of care therapy to reduce the risk of non-fatal stroke in adults with type 2 diabetes mellitus who have multiple cardiovascular risk factors or established cardiovascular disease |
| 09/22/2020 |
GN
| TRULICITY® (dulaglutide) est indiqué comme traitement d'appoint à un régime alimentaire, à l'exercice et au traitement standard pour réduire le risque d'accident vasculaire cérébral non mortel chez les adultes atteints de diabète de type 2 qui présentent des facteurs de risque cardiovasculaires multiples ou une maladie cardiovasculaire établie |
| 09/17/2020 |
GN
| Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial |
| 09/17/2020 |
GN
| Le baricitinib en association avec le remdésivir réduit le temps de guérison chez les patients hospitalisés atteints de la COVID-19 et participant à l'étude ACTT-2 commanditée par le NIAID |
| 09/16/2020 |
GN
| Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting |
| 09/16/2020 |
GN
| Lilly dévoile des données de validation de principe concernant l'anticorps neutralisant LY-CoV555 pour le traitement de la COVID-19 en contexte ambulatoire |
| 06/07/2020 |
GN
| Junshi Biosciences Announces Dosing of First Healthy Volunteer in Phase I Clinical Study of SARS-CoV-2 Neutralizing Antibody JS016 in China |
| 05/26/2020 |
GN
| Nature Publishes Preclinical Characterization and Primate Efficacy Data on Junshi Biosciences' COVID-19 Neutralizing Antibodies |
| 05/04/2020 |
GN
| Junshi Biosciences and Lilly to Co-develop Antibody Therapies for the Prevention and Treatment of COVID-19 |
| 10/09/2019 |
GN
| Verzenio™ (abemaciclib) Significantly Extends Life by a Median of 9.4 Months for Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2 Study |
| 07/17/2019 |
GN
| AC Immune Initiates Phase 1 Study of ACI-3024 Small Molecule Tau Morphomer™, an Investigational Treatment for Alzheimer's Disease |
| 03/25/2019 |
GN
| Recent Analysis Shows Mastercard, Halliburton, Keysight Technologies, Eli Lilly, Wabash National, and Regeneron Pharmaceuticals Market Influences — Renewed Outlook, Key Drivers of Growth |
| 02/08/2019 |
GN
| New Research Coverage Highlights Eli Lilly, Newell Brands, Novanta, Carrols Restaurant Group, 8x8, and Quanta Services — Consolidated Revenues, Company Growth, and Expectations for 2019 |
| 02/01/2019 |
GN
| Lilly and Loxo Oncology Announce Expiration of HSR Act Waiting Period in Connection with Proposed Transaction |
| 01/15/2019 |
GN
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Regarding Whether the Sale of Loxo Oncology, Inc. to Eli Lilly and Company is Fair to Shareholders |
| 01/09/2019 |
GN
| MERGER ALERT – BDMS, LOXO and MB: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies |
| 01/09/2019 |
GN
| Report: Exploring Fundamental Drivers Behind Virtusa, Eli Lilly, Cree, NewJersey Resources, Getty Realty, and PennantPark Investment — New Horizons, Emerging Trends, and Upcoming Developments |
| 01/07/2019 |
GN
| Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Loxo Oncology, Inc. (LOXO) on Behalf of Stockholders and Encourages LOXO Investors to Contact the Firm |
| 01/07/2019 |
GN
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Loxo Oncology, Inc. to Eli Lilly and Company is Fair to Shareholders |
| 01/07/2019 |
GN
| Lilly Announces Agreement To Acquire Loxo Oncology |
| 12/18/2018 |
GN
| Lilly and Aduro Biotech Announce Research Collaboration and License Agreement to Develop Novel Immunotherapies |
| 12/03/2018 |
GN
| Investor Expectations to Drive Momentum within Virtu Financial, Fate Therapeutics, Tandem Diabetes Care, Eli Lilly, Griffon, and Coherus BioSciences — Discovering Underlying Factors of Influence |
| 07/27/2018 |
GN
| New Research: Key Drivers of Growth for ICU Medical, A. Schulman, Verso, Eli Lilly, Spectrum Pharmaceuticals, and Intuit — Factors of Influence, Major Initiatives and Sustained Production |
|
|